FDA Alerts

FDA
FDA
FDA: Use of General Anesthetics, Sedatives May Harm Young Children
12/16/2016
Children’s brain development may be adversely affected by the use of general anesthetic and sedation drugs, the FDA said in a warning statement.
12/16/2016
Atopic Dermatitis
Atopic Dermatitis
FDA approves Pfizer's eczema ointment
12/15/2016
By Reuters Staff
12/15/2016
FDA
FDA
FDA Approves New Treatment Option for Eczema
12/14/2016
The FDA has approved Eucrisa (crisaborole) ointment for the treatment of mild to moderate eczema (atopic dermatitis) in patients aged 2 years and older.
12/14/2016
FDA
FDA
FDA Approves New Combination Drug for Type 2 Diabetes
12/13/2016
The FDA has approved Synjardy XR (empagliflozin and metformin hydrochloride extended-release) tablets for the treatment of adults with type 2 diabetes.
12/13/2016
FDA Alerts
FDA Alerts
FDA Approves New Combination Drug for Type 2 Diabetes
12/13/2016
The FDA has approved Synjardy XR (empagliflozin and metformin hydrochloride extended-release) tablets for the treatment of adults with type 2 diabetes.
12/13/2016
Diabetes Q&A
Diabetes Q&A
FDA Approves New Indication for Empagliflozin
12/02/2016
The FDA has approved Jardiance (empagliflozin) for the reduction of risk of cardiovascular death in adults with type 2 diabetes mellitus and cardiovascular disease.
12/02/2016
FDA Alerts
FDA Alerts
FDA Approves New Indication for Empagliflozin
12/02/2016
The FDA has approved Jardiance (empagliflozin) for the reduction of risk of cardiovascular death in adults with type 2 diabetes mellitus and cardiovascular disease.
12/02/2016
Vaccines
Vaccines
Flu Vaccine: Age Indication Approved
11/30/2016
The FDA has approved the expansion of the age indication for FluLaval Quadrivalent.
11/30/2016
Diabetes Q&A
Diabetes Q&A
FDA Approves Xultophy for Adults with Type 2 Diabetes
11/29/2016
The FDA approved Xultophy 100/3.6 for the reduction of A1c in adults with type 2 diabetes inadequately controlled by basal insulin or liraglutide alone.
11/29/2016
Diabetes Q&A
Diabetes Q&A
FDA Approves New Option for Type 2 Diabetes (Soliqua 100/33)
11/29/2016
The FDA has approved Soliqua 100/33 for the treatment of adults with type 2 diabetes that has been inadequately controlled with basal insulin or lixisenatide.
11/29/2016